Track Rapport Therapeutics, Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Rapport Therapeutics, Inc. Common Stock RAPP · Stock Open Rapport Therapeutics, Inc. Common Stock in new tab

32.19 USD
EPS
-3.03
P/B
3.66
ROE
-39.96
Beta
1.22
Target Price
62.88 USD
Loading chart...
Key Metrics
Earnings dateNov. 5, 2026
EPS-3.03
Book Value8.82
Price to Book3.66
Debt/Equity2.39
% Insiders3.903%
Estimates
Forward P/E-6.17
Forward EPS-5.23
Target Mean Price62.88

DCF Valuation

Tweak assumptions to recompute fair value for Rapport Therapeutics, Inc. Common Stock (RAPP)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Rapport Therapeutics, Inc. Common Stock Logo Rapport Therapeutics, Inc. Common Stock Analysis (RAPP)

USA Official Website Stock

Is Rapport Therapeutics, Inc. Common Stock a good investment? Rapport Therapeutics, Inc. Common Stock (RAPP) is currently trading at 32.19 USD. Market analysts have a consensus price target of 62.88 USD. This suggests a potential upside from current levels.

Earnings Schedule: Rapport Therapeutics, Inc. Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -5.23.

Investor FAQ

Does Rapport Therapeutics, Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Rapport Therapeutics, Inc. Common Stock?

Rapport Therapeutics, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -3.03.

Company Profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Exchange Ticker
US RAPP
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion